Friday, 16 October 2026European Markets

PROACTIS SA Stock Bearish By 16% In The Last 5 Sessions

Loading stream...

proactis sa, an established source-to-pay software solution provider based in france, has suffered an alarming plunge in share value over just five sessions, plunging by 16.67% - from eur0.1 to eur0.08 according to tuesday 14:11 est recording. this marked loss will certainly cause alarm among investors.

unexpected dip in france's stock market index

france's premier stock market index, cac 40, has taken an unexpected downwards spiral this week with an almost 1.35 per cent decrease to eur7,220.92. this follows two consecutive sessions of gains and underscores oscillatory market conditions.

disturbing statistics from proactis sa

proactis sa recently closed at an unsettling eur0.10 mark, marking an alarming 35.14% decline from its annual high point of eur0.15. with proactis offering procurement machinery, invoice capture services and system administration solutions among others, investors with an interest in software solution markets may take notice of its precipitous fall.

earnings per share indicate financial trouble

earnings per share (eps) provides an indicator of risks to proactis sa's financial health. with an eps value of eur-0.01, proactis is currently in rough waters, showing evidence of minor loss per distributed share.

negative return on equity raises concerns

zooming closer, proactis sa's return on equity (roe), an essential measure of business profitability relative to shareholder equity, was at an alarming negative -3.88% for its trailing twelve month period. this underperformance calls into question asset management practices and raises serious doubts as to their adequacy - further prompting doubt about investing in proactis sa stocks at this juncture. therefore, potential investors must monitor developments closely before taking action.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com